Werewolf Therapeutics Reports WTX-124 and WTX-330 Clinical Data at SITC 2026
Werewolf Therapeutics presented clinical data for WTX-124 and WTX-330, showing antitumor activity in advanced solid tumors. WTX-124's recommended Phase 2 dose was aligned with the FDA, and it demonstrated durable responses. WTX-330 showed a partial response in a gallbladder cancer patient and was well tolerated.
How this was made

The 30-second read
Why it matters
The disclosed Phase 1/2 data provide the first efficacy readout for its lead programs, which could materially affect the stock price.
Market read
First‑time disclosure of trial outcomes for a micro‑cap biotech, likely to generate short‑term price movement.
What to watch
Potential regulatory scrutiny of combination with pembrolizumab and competitive pipeline dynamics.
Background
Werewolf Therapeutics (HOWL) is a clinical‑stage biotech focused on engineered cytokine therapeutics.
Ticker impact
Werewolf Therapeutics filed an 8‑K reporting new Phase 1/2 clinical data for WTX‑124 and WTX‑330, including dose recommendations and partial responses.
potential upside as traders price in efficacy signals
First disclosure of durable responses and a confirmed partial response provides material new information for a micro‑cap biotech.
Market effects
Early data could boost interest in IL‑12/STAT4 pathway programs across oncology.
Limited to US biotech investors; no broader regional effect.
Modest, confined to specialty oncology investors.
Counterpoint
Data are early‑stage; efficacy may not translate to later trials, risk of disappointment.
Key entities
- companyWerewolf Therapeutics, Inc.
Issuer of the clinical data.
- drug_candidateWTX-124
IL-12 cytokine fusion protein evaluated in solid tumors.
- drug_candidateWTX-330
IL-12 cytokine fusion protein with partial response observed.

